

Sun Pharmaceutical Industries Limited  
SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
CIN: L24230GJ1993PLC019050  
www.sunpharma.com



**FOR IMMEDIATE RELEASE**

## **Sun Pharma Chairman, Israel Makov to retire on completion of term**

**Mumbai, India, August 3, 2022:** Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies), today announced that its Chairman and member of the Board, Mr Israel Makov, will retire from the company upon the completion of his current term post Sun Pharma's Annual General Meeting on August 29, 2022, after having led the organisation for 10 years. He was appointed a Board member and the Chairman in 2012.

Under his leadership, Sun Pharma transformed from a US\$ 1.7 billion organisation focusing on India and the US into the world's fourth largest specialty generic pharmaceutical company operating across 100+ markets with a turnover of over US\$ 5 billion. Leading the company's global expansion, he guided the acquisition of Ranbaxy in 2014, making Sun Pharma the leader in the Indian pharmaceutical market and a strong player globally. Mr Makov helped steer the company to pursue its strategy of building a global pipeline of specialty products.

Mr Israel Makov said "I was fortunate to be part of the thrilling journey of Sun Pharma becoming a major global player in the pharmaceutical industry. I especially enjoyed working with the talented executives of Sun Pharma who participated in the company's transformation and successfully led the process of change. I am proud of what this incredible company has accomplished and am grateful to my colleagues and all the members of the Board for their trust and support."

Sharing his thoughts on the contributions of Mr Israel Makov, Sun Pharma Managing Director, Mr Dilip Shanghvi said, "We thank Mr Makov for his visionary leadership and his contribution towards making Sun Pharma a global pharmaceutical company. I have always admired his business acumen and strategic orientation. Mr Makov has played a significant role in Sun Pharma's global expansion in the last decade. He guided the company into its next phase of growth with focus on innovation and adoption of newer technologies. The Board is sincerely grateful to Mr Makov for his dedication and wishes him all the best for the future."

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited  
SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
CIN: L24230GJ1993PLC019050  
www.sunpharma.com



**Disclaimer:**

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

**About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)**

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across six continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit [www.sunpharma.com](http://www.sunpharma.com) and follow us on Twitter @SunPharma\_Live.

**Contacts:**

**Investors:**

Nimish Desai  
Tel +91 22 4324 4324, Xtn 2778  
Tel Direct +91 22 4324 2778

**Mobile** +91-98203 30182

**E mail** [nimish.desai@sunpharma.com](mailto:nimish.desai@sunpharma.com)

**Media:**

Gaurav Chugh  
Tel +91 22 4324 4324, Xtn 5373  
Tel Direct +91 22 4324 5373

**Mobile** +91 98104 71414

**E mail** [gaurav.chugh@sunpharma.com](mailto:gaurav.chugh@sunpharma.com)

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.